Delivery Order SPE2DR25D9222-SPE2DR26FHLC7
Award Date 4/6/26
Potential Completion Date 4/7/26
Potential Value $6.1K
Federal Agency
Ultimate Awardee
Not listed PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Park Ridge, IL 60068, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Defense Logistics Agency's Medical Supply Chain issued a $1,605.15 delivery order to DMS Pharmaceutical Group Inc. on April 1, 2026, for procainamide 1 gram/10 mL vials. The order is issued under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V), a Defense Logistics Agency indefinite delivery contract established to supply pharmaceutical products and medical consumables to Department of Defense healthcare facilities worldwide. DMS Pharmaceutical Group Inc. is a...
- The Defense Logistics Agency's Medical Supply Chain division issued a $1,605.15 delivery order to DMS Pharmaceutical Group Inc. on April 1, 2026, for procainamide 1 gram/10 mL vials. The order is issued under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V), a Defense Logistics Agency indefinite delivery contract supporting pharmaceutical and medical consumable supply to Department of Defense healthcare facilities worldwide. DMS Pharmaceutical Group Inc. is a woman-owned...
- The Defense Logistics Agency's Medical Supply Chain issued a $1,605.15 delivery order to DMS Pharmaceutical Group Inc. on March 2, 2026, for procainamide 1 gram/10 mL vials under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) indefinite delivery contract. PPV-G GEN V is the Defense Logistics Agency's $30.3 billion pharmaceutical prime vendor acquisition strategy authorizing issuance of firm fixed-price delivery orders for branded and generic prescription drugs,...
- The Defense Logistics Agency's Medical Supply Chain issued a $1,605.15 delivery order to DMS Pharmaceutical Group Inc. on April 3, 2026, for procainamide 1 gram/10 mL vials. The order was issued under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V), a Defense Logistics Agency indefinite delivery contract supporting pharmaceutical supply to military healthcare facilities worldwide. DMS Pharmaceutical Group is a woman-owned small business pharmaceutical wholesaler based...
- The Defense Logistics Agency's Medical Supply Chain issued a $1,605.15 delivery order to DMS Pharmaceutical Group Inc. on April 1, 2026, for Procainamide 1 gram/10 mL vial (10 mL), with an ultimate completion date of April 2, 2026. This delivery order is issued under the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V), a $499.999 billion single-award IDC with a ceiling value of $499,999,999 and completion through December 31, 2036. The program...
- The Defense Logistics Agency's Medical Supply Chain division awarded a delivery order valued at $3,210.30 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Procainamide 1 gram/10 mL vials. The contract, issued on January 13, 2026, with an ultimate completion date of January 14, 2026, operates under a firm fixed-price structure with no set-aside designation. This delivery order is issued under DMS...
- The Defense Logistics Agency issued a $1,186.64 delivery order to DMS Pharmaceutical Group Inc. on March 7, 2026, under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) for pharmaceutical products and medical consumables. DMS Pharmaceutical Group Inc. is a woman-owned small business. The PPV-G GEN V is a Defense Logistics Agency indefinite delivery contract supporting pharmaceutical supply to Department of Defense military healthcare facilities worldwide, with a $499.9...
- The Defense Logistics Agency issued a $17,866.52 delivery order to DMS Pharmaceutical Group Inc. on March 3, 2026, under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) for pharmaceutical products to support Department of Defense healthcare operations. PPV-G GEN V is a Defense Logistics Agency indefinite delivery contract with a $499,999,999 ceiling and a December 31, 2036 ultimate completion date. DMS Pharmaceutical Group is a woman-owned small business...
- The Defense Logistics Agency issued a $12,066.35 delivery order to DMS Pharmaceutical Group Inc. on March 23, 2026, under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) for pharmaceutical products and medical consumables. DMS Pharmaceutical Group Inc. is a woman-owned small business. PPV-G GEN V is a Defense Logistics Agency indefinite delivery contract supporting pharmaceutical supply to Department of Defense healthcare facilities worldwide; the parent contract...
- The Defense Logistics Agency issued a $2,514.42 delivery order to DMS Pharmaceutical Group Inc. on April 3, 2026, under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) for pharmaceutical products. Ultimate completion is April 8, 2026. PPV-G GEN V is the Defense Logistics Agency's indefinite delivery contract supporting pharmaceutical supply to Department of Defense medical facilities worldwide, with a $499.9 billion total program ceiling. DMS Pharmaceutical Group is a...